Sustained release delivery of amphetamine salts
View Patent ↗A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR® type pulsatile formulations.
1. A pharmaceutical composition comprising a mixture of dextro- and levo-amphetamine and/or salt(s) thereof and a sustained release coating or matrix which comprises an amount of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, zein (prolamine from corn), a poly(meth)acrylate, microcrystalline cellulose or poly(ethylene oxide) effective to achieve continuous sustained release of said amphetamines and/or salt(s) to provide a mean plasma concentration profile in human ADHD patients which is substantially the same as the dextroamphetamine XR profile and/or the levoamphetamine XR profile of FIG. 1 over the course of the first twelve hours after administration, for a 20 mg total dose, or to provide a profile directly proportional to said XR profile(s) for a total dose other than 20 mg.
2. The composition of claim 1 , comprising a mixture of dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate and amphetamine sulfate.
3. The pharmaceutical composition of claim 2 , comprising equal amounts by weight of dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate and amphetamine sulfate.
4. The pharmaceutical composition of claim 1 , wherein said amphetamines and/or salt(s) are provided in a core which is coated with a coating comprising a pharmaceutically acceptable water-insoluble film-former providing sustained release or other polymer providing sustained release.
5. The pharmaceutical composition of claim 4 , wherein the coating further comprises a dissolution regulating agent.
6. A method for treating attention deficit hyperactivity disorder which comprises administering to a human patient in need thereof a pharmaceutical composition of claim 1 .
7. A pharmaceutical composition comprising a mixture of dextro- and levo-amphetamine and/or salt(s) thereof and a sustained release coating or matrix which comprises an amount of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, zein (prolamine from corn), a poly(meth)acrylate, microcrystalline cellulose or poly(ethylene oxide) effective to achieve continuous sustained release of said amphetamines and/or salts to provide a mean plasma concentration profile in human ADHD patients which has substantially the same initial slope as the dextroamphetamine XR profile and/or the levoamphetamine XR profile of FIG. 1 from 2 hours to 4 hours after administration, for a 20 mg total dose, or respective initial slope(s) from 2 hours to 4 hours after administration directly proportional to that of said XR profile(s) for a total dose other than 20 mg.
8. A method for treating attention deficit hyperactivity disorder which comprises administering to a human patient in need thereof a pharmaceutical composition of claim 7 .
9. A pharmaceutical composition comprising a mixture of dextro- and levo-amphetamine and/or salt(s) thereof and a sustained release coating or matrix which comprises an amount of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, zein (prolamine from corn), a poly(meth)acrylate, microcrystalline cellulose or poly(ethylene oxide) effective to achieve continuous sustained release of said amphetamines and/or salt(s) to provide a mean plasma concentration profile in human ADHD patients which has an initial slope from 2 hours to 4 hours after administration of about 3.7 to about 11.4 ng/(mL hr) for dextroamphetamines and/or about 1.4 to about 3 ng/(mL hr) for levoamphetamines, all at a total amphetamine dose of 20 mg, or respective initial slope(s) from 2 hours to 4 hours after administration directly proportional thereto for a total dose other than 20 mg.
10. A method for treating attention deficit hyperactivity disorder which comprises administering to a human patient in need thereof a pharmaceutical composition of claim 9 .
11. A pharmaceutical composition comprising a mixture of dextro- and levo-amphetamine and/or salt(s) thereof and a sustained release coating or matrix which comprises an amount of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, zein (prolamine from corn), a polly(meth)acrylate, microcrystalline cellulose or poly(ethylene oxide) effective to achieve continuous sustained release of said a amphetamines and/or salt(s) to provide a means plasma concentration profile in human ADHD patients which has an initial slope from 2 hours to 4 hours after administration of about 4 to about 8 ng/(mL hr) for dextroamphetamines and/or about 1.5 to about 2.2 ng/(mL hr) for levoamphetamines, all at a total amphetamine dose of 20 mg, or respective initial slope(s) from 2 hours to 4 hours after administration directly proportional thereto for a total dose other than 20 mg.
12. A pharmaceutical composition comprising a mixture of dextro- and levo-amphetamine and/or salt(s) thereof and a sustained release coating or matrix which comprises an amount of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, zein (prolamine from corn), a poly(meth)acrylate, microcrystalline cellulose or poly(ethylene oxide) effective to achieve continuous sustained release of said amphetamine and/or salt(s) to provide a mean plasma concentration profile in human ADHD patients which has an AUC of 556.6 mg hr/mL±20% and a C max of 28.0 ng/mL±20% for dextroamphetamine and/or an AUC of 205.1 ng hr/mL±20% and a C max of 8.7 ng/mL±20% for levoamphetamine, for a 20 mg total dose, or respective AUC and Cmax values directly proportional thereto for a total dose other than 20 mg.
13. A method for treating attention deficit hyperactivity disorder which comprises administering to a human patient in need thereof a pharmaceutical composition comprising a mixture of dextro- and levo-amphetamine and/or salt(s) thereof and a sustained release coating or matrix which comprises an amount of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, zein (prolamine from corn), a poly(meth)acrylate, microcrystalline cellulose or poly(ethylene oxide) effective to achieve sustained continuous release of said amphetamine and/or salt(s) to provide a mean plasma concentration profile in human ADHD patients which has an AUC of 556.6 mg hr/mL±20% and a C max of 28.0 ng/mL±20% for dextroamphetamine and/or an AUC of 205.1 ng hr/mL±20% and a C max of 8.7 ng/mL±20% for levoamphetamine, for a 20 mg total dose, or respective AUC and Cmax values directly proportional thereto for a total dose other than 20 mg.
14. A pharmaceutical composition comprising a mixture of dextro- and levo-amphetamine and/or salt(s) thereof and a sustained release coating or matrix which comprises an amount of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, zein (prolamine from corn), a poly(meth)acrylate, microcrystalline cellulose or polyethylene oxide) effective to achieve about a first order sustained dissolution release of said amphetamines and/or salt(s), which has an AUC of 556.6 mg hr/mL±20% and a C max of 28.0 ng/mL±20% for dextroamphetamine and/or an AUC of 205.1 ng hr/mL±20% and a C max of 8.7 mg/mL±20% for 1 levoamphetamine, for a 20 mg total dose, or respective AUC and Cmax values directly proportional thereto for a total dose other than 20 mg.
15. A pharmaceutical composition comprising a mixture of dextro- and levo-amphetamine salt(s) thereof and a sustained release coating or matrix which comprises an amount of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, zein (prolamine from corn), a poly(meth)acrylate, microcrystalline cellulose or poly(ethylene oxide) effective to achieve a single sustained dissolution release of said amphetamines and/or salt(s), which has an AUC of 556.6 mg hr/mL±20% and a C max of 28.0 mg/mL±20% for dextroamphetamine and/or an AUC of 205.1 ng hr/mL±20% and a C max of 8.7 ng/mL±20% for levoamphetamine, for a 20 mg total dose, or respective AUC and Cmax values directly proportional thereto for a total dose other than 20 mg.
16. The pharmaceutical composition of claim 1 , 16, 17, 18, 21, 31 or 32 comprising a sustained release matrix.
17. The pharmaceutical composition of claim 16 wherein said sustained release matrix comprises ethyl cellulose.
18. A method for treating attention deficit hyperactivity disorder which comprises administering to a human patient in need thereof a pharmaceutical composition of claim 17 .
19. The pharmaceutical composition of claim 1 , 7 , 9 , 11 , 12 , 14 , or 15 comprising a mixture of dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate and amphetamine sulfate.
20. The composition of claim 19 wherein said coating or matrix comprises ethyl cellulose.
21. The pharmaceutical composition of claim 1 , 7 , 9 , 11 , 12 , 14 or 15 wherein said formulation comprises said amphetamines and/or salt(s) in a core which is coated with a sustained release coating.
22. The pharmaceutical composition of claim 21 wherein said coating comprises ethyl cellulose.
23. The pharmaceutical composition of claim 1 , 7 , 9 , 11 , 12 , 14 or 15 wherein said formulation comprises a core coated with a coating comprising said amphetamines and/or salt(s), which amphetamine coated core is coated with a sustained release coating comprising ethyl cellulose.
24. The pharmaceutical composition of claim 1 , 7 , 9 , 11 , 12 , 14 or 15 wherein said formulation comprises a core coated with a coating comprising said amphetamines and/or salt(s), which amphetamine coated core is coated with a sustained release coating comprising a water insoluble polymer.
25. The pharmaceutical composition of claim 1 , 7 , 9 , 11 , 12 , 14 or 15 wherein the dissolution release profile of said amphetamines and/or salt(s) is first order.
26. The pharmaceutical composition of claim 25 wherein said release profile is determined in a dissolution profile test.
27. The pharmaceutical composition of claim 1 , 7 , 9 , 11 , 12 , 14 or 15 wherein said sustained release coating or matrix comprises polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, microcrystalline cellulose or poly(ethylene oxide).
28. The pharmaceutical of claim 1 , 7 , 9 , 11 , 12 , 14 or 15 wherein said coating or matrix comprises polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate or ethyl cellulose.
29. The pharmaceutical composition of claim 1 , 7 , 9 , 11 , 12 , 14 or 15 comprising a sustained release coating.
30. The pharmaceutical composition of claim 29 wherein said sustained release coating comprises ethyl cellulose.
31. A pharmaceutical composition of claim 1 , 9 , 11 , 12 , 14 or 15 wherein said sustained release coating or matrix has pH independent dissolution release.
32. A pharmaceutical composition of claim 9 , 11 , 12 , 13 , 22 , 14 or 15 wherein said stated numerical value range is achieved for dextroamphetamine.
33. A pharmaceutical composition of claim 9 , 11 , 12 , 13 , 22 , 14 or 15 wherein said stated numerical value range is achieved for levoamphetamine.
34. A pharmaceutical composition of claim 9 , 11 , 12 , 13 , 22 , 14 or 15 wherein said stated numerical value range is achieved for both dextroamphetamine and levoamphetamine.
35. A pharmaceutical composition comprising a mixture of dextro- and levo-amphetamine and/or salt(s) thereof and a sustained release coating which comprises an amount of ethyl cellulose effective to achieve continuous sustained release of said amphetamine and/or salt(s) to provide a mean plasma concentration profile in human ADHD patients which has an AUC of 556.6 mg hr/mL±20% and a C max of 28.0 ng/mL±20% for dextroamphetamine and/or an AUC of 205.1 ng hr/mL±20% and a C max of 8.7 ng/mL±20% for levoamphetamine, for a 20 mg total dose, or respective AUC and Cmax values directly proportional thereto for a total dose other than 20 mg.
36. The pharmaceutical composition of claim 35 comprising a mixture of dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate and amphetamine sulfate.
37. The pharmaceutical composition of claim 36 wherein said formulation comprises amphetamine coated cores, coated with a coating comprising ethyl cellulose.